STK11 and lung adenocarcinoma: Notably, one patient with LKB1 mutated advanced lung adenocarcinoma showed stable disease after receiving 10 mg of everolimus orally for 28 days, supporting the potential clinical utility of everolimus for treating LKB1 mutant tumors.